Cupferron

Cupferron

SCHEMBL101948

O=NN(O)c1ccccc1.[Fe]

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
ALOX15 P16050 1/20 0.54
NPSR1 Q6W5P4 2/20 0.42
HSP90AA1 P07900 1/20 0.36
ESR1 P03372 1/20 0.36
KMT2A Q03164 3/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
GLA P06280 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PKM P14618 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cupferron SCHEMBL1059593 0.98 ALDH1A1 (0.52) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL37151 0.97 ALDH1A1 (0.56) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL471987 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL21670426 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL52291 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL7506189 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL94436 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL21670430 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL7513315 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1
Cupferron SCHEMBL1719170 0.95 ALDH1A1 (0.54) ALDH1A1ALOX15NPSR1HSP90AA1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115838187-B Microwave-assisted organic phase ultra-small ferrite nano-particles and preparation method thereof 西安超磁纳米生物科技有限公司 2024-06-04 CN claimed
CN-112299489-B Ultra-small iron oxide nanoparticles and preparation method and application thereof 西安超磁纳米生物科技有限公司 2022-10-28 CN claimed
US-20210308284-A1 METAL ATOM CLUSTER-EMBEDDED MAGNETIC IRON OXIDE NANOPARTICLE (MION), AND PREPARATION METHOD AND APPLICATION THEREOF XI'AN SUPERMAG BIO-NANOTECH CO., LTD. (CN) 2021-10-07 US claimed
US-20150225332-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE IDEMITSU KOSAN CO., LTD. (JP) 2015-08-13 US claimed
US-20140235894-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE IDEMITSU KOSAN CO., LTD. (JP) 2014-08-21 US claimed
EP-2664611-A1 Method for producing alpha,beta-unsaturated carboxylic acid-N,N-disubstituted amide and method for producing 3-alkoxycarboxylic acid-N,N-disubstituted amide Idemitsu Kosan Co., Ltd (JP) 2013-11-20 EP claimed
US-20120088931-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE IDEMITSU KOSAN CO., LTD. (JP) 2012-04-12 US claimed
CN-115838187-B Microwave-assisted organic phase ultra-small ferrite nano-particles and preparation method thereof 西安超磁纳米生物科技有限公司 2024-06-04 CN disclosed
CN-115520907-A Ultra-small ferrite nano-particles with active groups, and preparation and application thereof 西安超磁纳米生物科技有限公司 2022-12-27 CN disclosed
US-20210308284-A1 METAL ATOM CLUSTER-EMBEDDED MAGNETIC IRON OXIDE NANOPARTICLE (MION), AND PREPARATION METHOD AND APPLICATION THEREOF XI'AN SUPERMAG BIO-NANOTECH CO., LTD. (CN) 2021-10-07 US disclosed
WO-2015140160-A1 MICELLAR NANOPARTICLES CONTAINING ANTITUMORAL GLYCOSIDES FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (ES) 2015-09-24 WO disclosed
EP-2921179-A1 Micellar nanoparticles containing antitumoral glycosides Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) (ES) 2015-09-23 EP disclosed
US-20150225332-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE IDEMITSU KOSAN CO., LTD. (JP) 2015-08-13 US disclosed
EP-2664611-A1 Method for producing alpha,beta-unsaturated carboxylic acid-N,N-disubstituted amide and method for producing 3-alkoxycarboxylic acid-N,N-disubstituted amide Idemitsu Kosan Co., Ltd (JP) 2013-11-20 EP disclosed
US-20120088931-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE IDEMITSU KOSAN CO., LTD. (JP) 2012-04-12 US disclosed
EP-2426103-A1 METHOD FOR PRODUCING ALPHA, BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE Idemitsu Kosan Co., Ltd. (JP) 2012-03-07 EP disclosed
EP-1123915-B1 Process for producing alpha, beta-unsaturated carboxylic acid esters and catalyst for use in such process NIPPON CATALYTIC CHEM IND (JP) 2004-07-28 EP disclosed
US-6541656-B2 Reacting an alpha, beta unsaturated carboxylic acid ester with a heterocyclic oxygen nitrogen, or sulfur compound NIPPON SHOKUBAI COMPANY, LTD. (JP) 2003-04-01 US disclosed
US-20010034300-A1 Reacting an alpha, beta unsaturated carboxylic acid ester with a heterocyclic oxygen nitrogen, or sulfur compound NIPPON SHOKUBAI COMPANY LTD. (JP) 2001-10-25 US disclosed
EP-1123915-A1 Process for producing alpha, beta-unsaturated carboxylic acid esters and catalyst for use in such process Nippon Shokubai Co., Ltd. (JP) 2001-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225332-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE FASN, NAAA, FAAH ALDH1A1 513/4885ALOX15 70/4885NPSR1 1200/4885
US-20140235894-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE FASN, NAAA, FAAH ALDH1A1 513/4885ALOX15 70/4885NPSR1 1200/4885
US-20120088931-A1 METHOD FOR PRODUCING ALPHA,BETA-UNSATURATED CARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE AND METHOD FOR PRODUCING 3-ALKOXYCARBOXYLIC ACID-N,N-DISUBSTITUTED AMIDE FASN, NAAA, FAAH ALDH1A1 513/4885ALOX15 70/4885NPSR1 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.